Nuclear beta-catenin as a surrogate of Wnt pathway activation was present in 39% (36/92) BRAF mutant cancers which was significantly lower than the rate observed in BRAF wild type cancers at 86% (36/42) (p < 0.0001) (Table 1). This evidence concerns the gene BRAF and cancer.